M&A / Deals MSD concludes Terns acquisition to expand CML pipeline Pharmaceutical TechnologyMSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).HematologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML). Hematology Read full story Post navigation Previous: FDA Expands Market Access, Authorizes New ENDS ProductsNext: MSD concludes Terns acquisition to expand CML pipeline Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
